QS295. Epidermal Growth Factor Receptor (EGFR) Over Expression in Microsatellite Unstable (MSI) Colorectal Cancer (CRC) Is Characterized by a Deletion Mutation in the 3’ UTR Poly (A) 13 Tract and Is not Associated With Intron 1 CA Repeat Length Variation

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Length Variation ◽

Ca Repeat ◽

Over Expression ◽

Intron 1 ◽

Epidermal growth factor receptor intron 1 polymorphism and microsatellite instability in sporadic colorectal cancer

Oncology Letters ◽

10.3892/ol.2020.12392 ◽

2020 ◽

Vol 21 (2) ◽

Author(s):

Sonja Marinović ◽

Kristina Vuković ◽

Anita Škrtić ◽

Mirko Poljak ◽

Sara Petek ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Microsatellite Instability ◽

Growth Factor Receptor ◽

Sporadic Colorectal Cancer ◽

Intron 1 ◽

Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer

Recent Patents on Anti-Cancer Drug Discovery ◽

10.2174/1574209199544168928 ◽

2009 ◽

Vol 999 (999) ◽

pp. 1-8

Author(s):

Anne Kendall ◽

Rosemary Lord ◽

Nick Maisey

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Receptor Antibodies

The inhibitory effect of ECG and EGCG dimeric procyanidins on colorectal cancer cells growth is associated with their actions at lipid rafts and the inhibition of the epidermal growth factor receptor signaling

Biochemical Pharmacology ◽

10.1016/j.bcp.2020.113923 ◽

2020 ◽

Vol 175 ◽

pp. 113923 ◽

Cited By ~ 1

Author(s):

Wei Zhu ◽

Mei C. Li ◽

Feng R. Wang ◽

Gerardo G. Mackenzie ◽

Patricia I. Oteiza

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Cancer Cells ◽

Growth Factor Receptor ◽

Inhibitory Effect ◽

Colorectal Cancer Cells ◽

Epidermal Growth ◽

Growth Factor Receptor Signaling

To Give or Not to Give Anti–Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies to Patients With KRAS G13D Mutation in Advanced Colorectal Cancer

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2011.10.005 ◽

2012 ◽

Vol 11 (2) ◽

pp. 85-87 ◽

Cited By ~ 1

Author(s):

Richard Kim ◽

Timothy Kubal

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Advanced Colorectal Cancer ◽

Growth Factor Receptor ◽

Impact of tumor epidermal growth factor receptor (EGFR) status on the outcomes of first-line FOLFOX-4 ± cetuximab in patients (pts) with RAS-wild-type (wt) metastatic colorectal cancer (mCRC) in the randomized phase 3 TAILOR trial

Annals of Oncology ◽

10.1093/annonc/mdw370.75 ◽

2016 ◽

Vol 27 ◽

pp. vi174 ◽

Cited By ~ 2

Author(s):

S. Qin ◽

J. Xu ◽

L. Wang ◽

Y. Cheng ◽

T. Liu ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Growth Factor Receptor ◽

Wild Type ◽

First Line ◽

Phase 3 ◽

PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2011.12.001 ◽

2012 ◽

Vol 11 (2) ◽

pp. 143-150 ◽

Cited By ~ 61

Author(s):

Arjun Sood ◽

Danielle McClain ◽

Radhashree Maitra ◽

Atrayee Basu-Mallick ◽

Raviraja Seetharam ◽

...

Keyword(s):

Gene Expression ◽

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Antibody Therapy ◽

Growth Factor Receptor ◽

Pten Gene ◽

Wild Type ◽

PD-013 A study level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors (EGFRIs) vs bevacizumab in patients with metastatic colorectal cancer (mCRC)

Annals of Oncology ◽

10.1093/annonc/mdv234.12 ◽

2015 ◽

Vol 26 ◽

pp. iv104

Author(s):

V. Heinemann ◽

F. Rivera ◽

B. O'Neill ◽

R. Koukakis ◽

J.H. Terwey ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Meta Analysis ◽

Growth Factor Receptor ◽

First Line ◽

Efficacy Data ◽

Optimizing Administration of Epidermal Growth Factor Receptor–Targeted Agents in the Treatment of Colorectal Cancer

Clinical Colorectal Cancer ◽

10.3816/ccc.2007.s.004 ◽

2007 ◽

Vol 6 ◽

pp. S60-S65 ◽

Cited By ~ 12

Author(s):

Eric Van Cutsem

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

Targeted Agents ◽

A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer

International Journal of Oncology ◽

10.3892/ijo.2018.4322 ◽

2018 ◽

Cited By ~ 3

Author(s):

Nobuhisa Matsuhashi ◽

Takao Takahashi ◽

Satoshi Matsui ◽

Toshiyuki Tanahashi ◽

Hisashi Imai ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Growth Factor ◽

Personalized Medicine ◽

Epidermal Growth Factor ◽

Therapeutic Strategy ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Novel Therapeutic

The pattern of epidermal growth factor receptor variation with disease progression and aggressiveness in colorectal cancer depends on tumor location

Oncology Letters ◽

10.3892/ol.2012.621 ◽

2012 ◽

Vol 3 (5) ◽

pp. 1129-1135 ◽

Cited By ~ 11

Author(s):

PETROS C. PAPAGIORGIS ◽

ADAMANTIA E. ZIZI ◽

SOPHIA TSELENI ◽

IOANNIS N. OIKONOMAKIS ◽

NIKOLAOS I. NIKITEAS

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Disease Progression ◽

Growth Factor Receptor ◽

Tumor Location ◽